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Decision aids that facilitate elements of
shared decision making in chronic illnesses:
a systematic review
Thomas H. Wieringa1* , Rene Rodriguez-Gutierrez2,3,4, Gabriela Spencer-Bonilla2,5, Maartje de Wit1, Oscar J. Ponce2,
Manuel F. Sanchez-Herrera2, Nataly R. Espinoza2, Yaara Zisman-Ilani6, Marleen Kunneman2,7, Linda J. Schoonmade8,
Victor M. Montori2 and Frank J. Snoek1
Abstract
Background: Shared decision making (SDM) is a patient-centered approach in which clinicians and patients work
together to find and choose the best course of action for each patient’s particular situation. Six SDM key elements
can be identified: situation diagnosis, choice awareness, option clarification, discussion of harms and benefits,
deliberation of patient preferences, and making the decision. The International Patient Decision Aid Standards
(IPDAS) require that a decision aid (DA) support these key elements. Yet, the extent to which DAs support these six
key SDM elements and how this relates to their impact remain unknown.
Methods: We searched bibliographic databases (from inception until November 2017), reference lists of included
studies, trial registries, and experts for randomized controlled trials of DAs in patients with cardiovascular, or chronic
respiratory conditions or diabetes. Reviewers worked in duplicate and independently selected studies for inclusion,
extracted trial, and DA characteristics, and evaluated the quality of each trial.
Results: DAs most commonly clarified options (20 of 20; 100%) and discussed their harms and benefits (18 of 20;
90%; unclear in two DAs); all six elements were clearly supported in 4 DAs (20%). We found no association between
the presence of these elements and SDM outcomes.
Conclusions: DAs for selected chronic conditions are mostly designed to transfer information about options and
their harms and benefits. The extent to which their support of SDM key elements relates to their impact on SDM
outcomes could not be ascertained.
Systematic review registration: PROSPERO registration number: CRD42016050320.
Keywords: Chronic illnesses, Decision aids, Shared decision making
Background
Shared decision making (SDM) is a patient-centered ap-
proach in which clinicians and patients work together to
find and choose (by taking into account the best avail-
able evidence, as well as the patients’ problems, values,
preferences, and contexts) the best course of action for
each patient’s particular situation [1], an approach that is
pertinent to the care of patients with chronic conditions
[2]. Decisions in the context of self-management of
chronic conditions differ from one-time decisions, as in
the former decisions can often be reconsidered [2]. Six
key elements of SDM can be identified from the litera-
ture: situation diagnosis, choice awareness, option clari-
fication, discussion of harms and benefits, patient
preferences deliberation, and making the decision [1–4].
As noted by Stiggelbout and others [5, 6], SDM pro-
motes actions that are needed, wanted, and more likely
to be implemented. A shared understanding and treat-
ment focused on patients’ health and life goals, as well
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as a stronger clinician-patient relationship, may also be
facilitated by SDM [7, 8].
An SDM interaction starts with a diagnostic conversa-
tion (situation diagnosis) [1]. This opening first focuses on
understanding the patient’s situation and establishing the
aspects that require action [1, 4]. When multiple reason-
able options are available, then the clinician should indi-
cate this and highlight the importance of the patient’s
preferences in deciding on the course of action (choice
awareness) [3]. Subsequently, the patient and clinician de-
liberate about the way each option fits and accommodates
within each patient’s situation (option clarification, discus-
sion of harms and benefits, and patient preferences delib-
eration). Finally, a decision is made by the clinician and
patient (making the decision) [2, 4].
SDM can be facilitated by decision aids (DAs) that
have been developed for use by clinicians and patients,
either during or in preparation for the clinical encounter
[9–11]. DAs can help patients choose an option that is
congruent with their values, reduce the proportion of
patients remaining undecided and/or who play a passive
role in the decision-making process, and improve patient
knowledge, decisional conflict, and patient-clinician
communication [11–15]. The International Patient Deci-
sion Aid Standards (IPDAS) Collaboration aims to en-
hance the quality and effectiveness of DAs by
establishing an evidence-informed framework for im-
proving their content, development, implementation,
and evaluation [16]. The IPDAS Collaboration defines a
DA as “a tool designed to help people participate in de-
cision making about health care options” [9], and devel-
oped a minimal set of standards for qualifying a tool as a
DA [17]. According to this minimal set, all SDM key ele-
ments, except making the decision, should be handled
by a tool in order to regard it as a DA [17]. Despite this
minimal set of qualifying criteria, investigators have
found that fostering choice awareness through the use of
a DA was not a prerequisite for fostering choice aware-
ness per se during the encounter [18]. Therefore, it is
unclear whether tools should support all qualifying
IPDAS criteria for these tools to support SDM. There-
fore, we define a DA in the current review as “any tool
designed to support SDM.”
To the best of our knowledge, there is no empirical
data to tell us which of the six key elements are sup-
ported by DAs and whether there is an association be-
tween support for these key elements and SDM
outcomes. We hypothesize that DAs that cover multiple
elements of SDM are more likely to have positive effects
on SDM outcomes, as well as on patient-reported out-
comes (PROs). With regard to surrogate and clinical
outcomes, there is no reason to expect a consistent re-
sponse. A previous systematic review of the effects of
DAs found that more detailed DAs better improve
knowledge and reduce some aspects of decisional con-
flict compared to simple DAs, and concluded that more
research is needed to evaluate the level of detail needed
in DAs [19]. The current review aims to meet this need
by studying the SDM elements incorporated in DAs and
their effect on SDM outcomes.
This review aims to (1) describe the SDM elements
present in DAs for patients with common chronic con-
ditions (cardiovascular, chronic respiratory diseases or
diabetes) tested in randomized controlled trials (RCTs),
and (2) determine an association between the key ele-
ments present and the effects of these DAs compared to
usual care or active controls on SDM outcomes (e.g.,
conversation duration, patient participation, knowledge,
and decisional conflict).
Methods
The protocol of this systematic review was previously
published [20] and registered in the International Pro-
spective Register of Systematic Reviews (PROSPERO
registration number: CRD42016050320; http://www.crd.
york.ac.uk/PROSPERO). The review is reported accord-
ing to the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guidelines [21].
Additional file 1 provides the PRISMA checklist.
Study eligibility
We searched RCTs comparing the use of DAs (any tool
designed to support SDM) to usual care or active con-
trols (except other DAs) in adults with cardiovascular
disease, chronic respiratory disease, or diabetes and
measuring their impact on SDM and health outcomes
(patient-reported, surrogate, and clinical outcomes). As
described in detail previously [20], we selected chronic
conditions that are most prevalent according to the
World Health Organization [22–24], most likely to re-
quire self-management, and for which decisions may be
revisited. We included all pertinent publications of an
eligible study. There were no exclusions based on lan-
guage or year of publication.
Information sources and search strategy
To identify all relevant publications, we performed sys-
tematic searches, in collaboration with a medical librar-
ian (LJS) in the bibliographic databases PubMed,
Embase.com, Web of Science, CINAHL (through
EBSCO), PsycINFO (through EBSCO), and the Cochrane
Library from inception to November 7th, 2017. Search
terms included MesH in PubMed, EMtree in Embase.
com, Cinahl headings in Cinahl, indexed terms from the
Thesaurus in PsycINFO, and free text terms. We used
free text only in the Cochrane Library and Web of Sci-
ence. Search terms compressing “shared decision mak-
ing” were used in combination with “cardiovascular
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diseases” OR “chronic respiratory diseases” OR “dia-
betes.” Search results were limited to RCTs. Duplicate
articles were excluded. All languages were accepted. The
full search strategies for all databases can be found in
Additional file 2. In early 2017, THW contacted by
e-mail and queried SDM experts participating in the
Facebook group “Shared@ Shared Decision Making Net-
work,” and in the LinkedIn groups “Platform SDM GB”
and “Shared Decision Making in Netherlands” for add-
itional eligible studies. THW also reviewed trial regis-
tries including http://isrctn.com, http://narcis.nl, http://
trialregister.nl, and http://www.clinicaltrials.gov. MFSH
reviewed the reference lists from included studies.
Study selection process
After deduplication, pairs of reviewers (two hired per-
sons, GS-B, RRG, and THW), working independently
and in duplicate, assessed each abstract for eligibility.
Studies considered potentially eligible by at least one re-
viewer were included for the full-text phase. THW and
RRG reviewed selected full-text articles independently
and in duplicate. Disagreements were resolved by a third
reviewer (GS-B or OJP).
Data collection process
Data about study and DA characteristics, study quality,
and outcomes were extracted by pairs of reviewers work-
ing in duplicate (two hired persons, RRG, MFSH, YZI,
and THW) with conflict resolved by a third reviewer
(GS-B, NRE, YZI, and RRG; YZI and RRG resolved con-
flicts of parts for which they did not collect data). We
used the definitions in Table 1 to determine which key
SDM components were present. Sets of three articles
were used to train and calibrate reviewers through
extraction and discussion of results among reviewers.
Outcomes collected were those most proximate to the
encounter of interest.
Risk of bias in individual studies
OJP and THW independently assessed the risk of bias
on outcome level at all domains of the Cochrane Collab-
oration’s tool for RCTs [25, 26], with disagreement re-
solved by consensus. Because blinding of patients and
clinicians to the use of conversation aids is not possible,
we ignored the two blinding factors. Otherwise, when
one or more of the five other domains was regarded as
being at high risk of bias, then the summary assessment
of the risk of bias was “high.” If one or more domain
was “unclear” and all others were “low risk,” then we
summarized the risk of bias as “unclear.” If all domains
were “low risk,” then the summary assessment of the
risk of bias was “low.”
Outcomes and data synthesis
Data on both SDM (e.g., conversation duration, patient
participation, knowledge, and decisional conflict) and
health outcomes (patient-reported, surrogate, and clin-
ical outcomes) were collected. Standardized mean differ-
ences (SMDs) together with their 95% confidence
intervals (95%-CIs) were calculated for continuous out-
comes using Review Manager 5.3 [27]. Odds ratios
(ORs) together with their 95% CIs were directly ex-
tracted from the reports. If the mean difference and/or
its standard error (SE) and 95% CI were not presented
in the article, then the SMD together with its 95% CI
were calculated by entering the mean score/value per
arm together with their standard deviations (SDs). If the
95% CI for an OR was not presented, then numbers for
every cell in the 2 × 2 table were inserted into Review
Manager 5.3 to be calculated. The SMD could not be
calculated when only interquartile ranges were reported.
We also summarize the data narratively according to
our protocol [20].
Missing data and author contact
All corresponding authors (or other authors if no re-
sponse after approximately 6 weeks) of included studies
were contacted through e-mail and, if no response, again
approximately 4 weeks later (although originally
planned, we did not contact authors by phone) to re-
quest missing data or clarifications. If the authors did
not respond or could not provide a missing standard de-
viation needed to calculate the SMD, then the SD of the
most comparable study with the same outcome and
measurement instrument was imputed.
Table 1 Definitions for the key elements of SDM in decision
aids (DAs)
Key element of SDM Definitions for this study [4, 18]
Situation diagnosis The DA explicitly describes the patient’s
problem.
Choice awareness The DA explicitly acknowledges that the
patient’s situation is mutable, that there is more
than one sensible way to address or change this
situation, and that patient input matters in
deciding how to proceed.




The DA explicitly explains the harms and
benefits of the available options.
Patient preferences
deliberation
The DA explicitly elicits the patient’s preferences
or explicitly motivates the parties to discuss
them.
Making the decision The DA explicitly elicits the patient’s wish to
make or defer a decision, asks for the patient’s
choice, or describes the patient’s choice.
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Results
Figure 1 describes the flow of the study selection. Chan-
ce-adjusted inter-reviewer agreement (k) for eligibil-
ity was only fair (k = 0.3–0.4) [28]. We found 24
articles reporting on 23 RCTs of 20 DAs (10 DAs
for cardiovascular disease, 2 DAs for respiratory dis-
eases, and 8 DAs for diabetes). The effectiveness of
Statin Choice was studied in three RCTs described
in four articles meeting our criteria and The Dia-
betes Medication Choice Decision Aid was studied
in two RCTs described in two separate articles.
Other DAs were studied in one RCT described in
one article. Additional file 3 presents the risk of bias
assessment on the outcome level per study. Besides
the study of Gagné et al. [29], all studies have an
unclear or high risk of bias for all outcomes assessed
in this review.
Table 2 shows the SDM elements supported per DA.
The elements were described as “unclear” if the DAs
were neither described clearly nor available for our in-
spection, and/or if reviewers were uncertain whether the
regarding element was included in the DA. The option
clarification element (included in 20 of 20 DAs; 100%)
and the harms and benefits discussion (included in 18 of
20 DAs; 90%; unclear in two DAs) are the elements most
commonly clearly included in the DAs. The other ele-
ments are less common and more uncertainty is present
whether these elements are included, especially with re-
gard to choice awareness (uncertain in 14 out of 20
DAs; 70%). All elements were clearly supported in four
DAs (20%). Table 2 also shows the DA effects on SDM
outcomes. We could not glean any association between
SDM elements present in the DAs and SDM outcomes.
Additional file 4 reports details of the DAs included here
Fig. 1 Flowchart of study selection
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and Additional file 5 their impact on SDM and health
outcomes. We imputed the SD for the decisional conflict
outcome for Mann et al. [30] using the SD found by
Weymiller et al. [31] for the same outcome in the same
context.
Discussion
This review presents an overview of chronic care DAs
developed and tested in RCTs, SDM elements they sup-
port, and their effects on SDM outcomes and health out-
comes. Most DAs support the clarification of options
and the discussion of their benefits and harms, while
other elements are less prevalent. Almost all trials were
at an unclear or high risk of bias, and no association be-
tween SDM elements supported in the DA on the one
hand and SDM outcomes achieved versus control on the
other hand could be determined.
SDM elements handled by DAs
Our analysis of SDM elements supported is consistent
with previous literature stating that most DAs focus and
are tested on providing information or discussing
choices rather than on creating empathic conversations
[53]. We could not, however, estimate the relationship
between the extent to which DAs support SDM ele-
ments and SDM outcomes.
Possibly, some SDM elements may have been left out
of DAs by design. This choice may depend on what fea-
tures were thought most important by the developers
(e.g., patient education, risk communication, preference
elicitation, or patient empowerment). The importance of
incorporation of SDM elements in DAs may be
situation-dependent, but the way this works is unclear.
Future research should clarify this situation-dependence
and eventually inform possible reconsideration of the
IPDAS minimum standards for DA qualification [17].
DA effects
The inability to find any empiric association between
features present and SDM outcomes prevents us from
using this evidence base to make recommendations
about the content of DAs for use in patients with
chronic conditions. Multiple factors potentially explain
the varying effects, including the following: whether a
patient decision aid or conversation aid is used [10],
chronicity of conditions [2], design process [54, 55], con-
text, target population [19], and degree of detail needed
[19]. Future studies may assess the dependency of DA
effects on these factors and their interactions with the
SDM elements.
Difficulties faced
Some difficulties were faced when conducting this re-
view. A major difficulty during the article selection was
the suboptimal reporting of DA characteristics. The aim
of DAs is not always explicitly described and if de-
scribed, it still may be questionable whether implement-
ing SDM is implicitly aimed for as the concept of SDM
itself is highly debatable [56]. Namely, a review found 31
separate concepts to explicate SDM [57]. Our ability to
categorize whether SDM elements were present was lim-
ited by the fact that some DAs were not available and/or
the description of the DA’s content was not clear and de-
tailed. The latter is in line with the literature [58, 59].
Even when DAs were available and/or content was
clearly described, it may not always be clear-cut whether
or not an element is handled. Therefore, data regarding
the SDM elements is based on reviewers’ judgments.
Furthermore, it may sometimes be unclear whether or
not a condition is chronic (e.g., aneurysms). These con-
ditions were included in this review in order to be as
comprehensive as possible, but the decisions to be made
may not be reversible over time or only to a limited ex-
tent. These aspects may have resulted in the fair
inter-rater agreement. Another difficulty was found in
the large methodological heterogeneity across studies
(e.g., measurement instruments, timing of outcome mea-
surements, and presentation of results).
More guidance is needed on the reporting of SDM ele-
ments and DA aims, the measurement instruments to
use in RCTs studying DA effects, as well as the timing of
outcome measurements and the way results are pre-
sented in articles. Furthermore, the quality of RCTs
studying DA effects can be improved. The new Stan-
dards for UNiversal reporting of patient Decision Aid
Evaluation studies (SUNDAE) checklist seems to meet
this need as it helps to ensure the high-quality reporting
of DA evaluation studies, as well as its intelligibility and
transparency [59].
Strengths and limitations
This review is the first to report on SDM elements in-
cluded in DAs developed for chronic conditions, and its
relations to a range of SDM outcomes. This review un-
derscores the importance of methodological improve-
ment of DA evaluation studies, which hopefully will be
attained by the new SUNDAE checklist [59].
Our review has some limitations. Since we were inter-
ested in the efficacy of DAs, we have limited our search
strategy to RCTs [60], which may have led to exclusion
of (well designed and developed) DAs that have not been
tested in trials. Finally, we limited our search strategy to
the most prevalent cardiovascular diseases, chronic re-
spiratory diseases, and diabetes [22–24], an incomplete
list of chronic diseases. This while a silver bullet of the
literature probably brings to light what is happening in
other chronic illnesses.
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Future research
Future research should focus on empirically testing
which SDM elements should be included in DAs, and
take situation-dependency into account. This warrants
studies with a sound methodology and low risk of bias
that are currently lacking.
Conclusions
Tools to promote SDM for patients with chronic condi-
tions support only some key recommended SDM ele-
ments thought to be important for SDM. The literature
has not examined the relationship between explicit sup-
port for these elements in DAs and SDM outcomes.
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